The aims of the UCSF-GIVI CFAR are to support a multi-disciplinary environment that promotes basic, clinical, epidemiologic, behavioral, and translational research in the prevention, detection, and treatment of HIV infection and AIDS and to further the programs of NIH institutes by providing unique and effectively managed activities propelling HIV research. CFAR applies effective leadership, open communications, educational opportunities, sound resource management, and strategic planning to link CFAR members across sites and scientific disciplines. The Center's leadership is committed to proactive management, transparency and continued program monitoring, evaluation, and readjustment. CFAR maintains an effective partnership with the UCSF AIDS Research Institute and with the Center for AIDS Prevention Studies. To catalyze multidisciplinary research, the Center manages six scientific cores (Clinical and Population Sciences, Immunology, Virology, Specimen Banking, Pharmacology, and International). The Clinical and Population Sciences Core facilitates access to appropriate clinical cohorts. The International Core, focused on a growing portfolio in Uganda, will build in-country capacity and collaborate with the Fogarty International Center in training. Expansion to other African sites is expected. Core Directors are charged with member outreach and soliciting new investigators to take advantage of the cutting edge technologies and assays available within the cores. Success of the scientific cores is assessed by the quality of the multidisciplinary science they stimulate and by the publications and successful grants to which they contribute. The CFAR Administrative Core maintains an electronic network, including videoconferencing, to connect and inform all CFAR members, organizes scientific seminars and symposia, and implements financial systems to monitor and report all CFAR funds, ensuring maximum CFAR effectiveness. The Developmental Core funds pilot and basic science grants. It supports the next generation of HIV science through mentored pilot grants and an extremely successful and ambitious formal mentoring program. The success of the UCSF-GIVI CFAR is evident in the scientific accomplishments of its investigators, its ability to galvanize fundamentally new science through its focus on innovative multidisciplinary HIV research, and the significant institutional support it receives from UCSF, the San Francisco Veterans Affairs Medical Center and the J. David Gladstone Institutes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-19
Application #
7938742
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
19
Fiscal Year
2010
Total Cost
$3,401,797
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Yukl, Steven A; Kaiser, Philipp; Kim, Peggy et al. (2018) HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med 10:
Roy, Monika; Holmes, Charles; Sikazwe, Izukanji et al. (2018) Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia. Clin Infect Dis 67:1269-1277
Kiniry, Brenna E; Hunt, Peter W; Hecht, Frederick M et al. (2018) Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection. J Immunol 200:1876-1888
Jeng, Mark Y; Hull, Philip A; Fei, Mingjian et al. (2018) Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1. J Exp Med 215:51-62
Chitre, Avantika S; Kattah, Michael G; Rosli, Yenny Y et al. (2018) A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathog 14:e1006806
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Leonard, Brandon; Brand, Toni M; O'Keefe, Rachel A et al. (2018) BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer Res 78:4331-4343
Wang, Chia-Ching; Thanh, Cassandra; Gibson, Erica A et al. (2018) Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv 2:3479-3482
Castillo-Mancilla, Jose R; Morrow, Mary; Boum, Yap et al. (2018) Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. J Acquir Immune Defic Syndr 77:507-513

Showing the most recent 10 out of 1541 publications